RxDoctor Payments DataLook up a doctor →

Selina McGee

Optometrist · Edmond, OKNPI 1720057607

Payments from drug & device makers

$1,175,707in general payments, 2019–2025

Across 1,740 payments — averaging $675.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$440K
  • Bausch & Lomb Americas Inc.$216K
  • Tarsus Pharmaceuticals, Inc.$114K
  • Oyster Point Pharma, Inc.$95K
  • Dompe US, Inc.$68K
  • Alcon$57K
  • plus $186K from 28 others
$1,875in research payments, 2019–2025

Across 1 payment — averaging $1875.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Oyster Point Pharma, Inc.$2K

What the payments were for

  • Consulting fees$355,25831%
  • Speaking & faculty fees$647,87157%
  • Travel & lodging$102,7699%
  • Food & beverage$40,5674%
  • Education$610%
  • Entertainment$1310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,175,707 in reported general payments places this provider in the 95th percentile of 714 optometrist providers in Oklahoma.

See all optometrist providers in Oklahoma

Medicare billing

Part B allowed, 2024
$89,325
Medicare patients
347
Services billed
1,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine75$95,740
XdemvyLotilaner28$52,555
MieboPerfluorohexyloctane/Pf35$26,131
CequaCyclosporine28$18,422
Cyclosporine20$14,420
TyrvayaVarenicline Tartrate14$13,433
LumiganBimatoprost13$3,754
Loteprednol Etabonate14$1,516
Latanoprost36$562
Timolol Maleate12$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$439,938$99,49488 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$113,636$52,55528 claims
Bausch & Lomb Americas Inc.Miebo$215,642$26,13135 claims
Sun Pharmaceutical Industries Inc.Cequa$54,407$18,42228 claims
Oyster Point Pharma, Inc.Tyrvaya$95,113$13,43314 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$20$1,51614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 714 optometrist providers in Oklahoma.

Other optometrist in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →